All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .
Biochem/physiol Actions
MEF2D (myocyte enhancer factor 2D) is a member of MEF2 family. It is majorly involved in the muscle and neuronal differentiation as a transcriptional activator. It is also associated with cardiac morphogenesis, blood vessel formation, and growth factor responsiveness. It has been reported that the presence of MEF2D activates muscle specific luciferase constructs. As a consequence, it increases expression of the muscle-specific gene, myosin heavy chain, and a marker for skeletal muscle differentiation. It has also been concluded that the expression of MEF2D is upregulated in the p21 cells. In hepatocellular carcinoma, MEF2D regulates transcription of G2-M transition-retarding genes. Thus, it proves that MEF2D is a tumor-promoting gene in human hepatocellular carcinoma.
